Alexion Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Alexion Pharmaceuticals, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – ALXN

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) to AstraZeneca PLC for $60.00 in cash and 2.1243 AstraZeneca American Depositary Shares for each Alexion share is fair to Alexion shareholders.

Halper Sadeh encourages Alexion shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at [phone] or [e-mail] or [e-mail].

The investigation concerns whether Alexion and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to: (1) obtain the best possible price for Alexion shareholders; (2) determine whether AstraZeneca is underpaying for Alexion; and (3) disclose all material information necessary for Alexion shareholders to adequately assess and value the merger consideration. On behalf of Alexion shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

Halper Sadeh encourages Alexion shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at [phone] or [e-mail] or [e-mail].

Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.